Phosphagenics solves oxycodone patch design problems and plans for new trial

Phosphagenics (ASX:POH) has solved the crystallisation problems with its oxycodone patch and is aiming to re-enter the clinic by the end of this quarter.

Phosphagenics (ASX:POH, OTCQX:PPGNY) is planning to take its oxycodone pain patch back into the clinic by the end of this quarter after design flaws were resolved.

The company had German drug development company tesa Labtec GmbH work on resolving crystallisation issues that were experienced with the original design.

Crystallisation is an issue because it potentially allows the oxycodone extracted and misused. Resolving these issues are key to seeing it approved by regulators.

tesa Labtec has experience in opioid patch development and specialises in self-adhesive products for a variety of purposes.

Phosphagenics now intends to take its TPM (targeted penetration matrix) patch with oxycodone to clinical trials before the end of the first quarter of this year, and will continue trials of its oxymorphone patch.

“Together these opioid candidates represent the implementation of the company’s strategy to leverage the powerful TPM platform delivery technology to develop a range of innovative transdermal products that are capable of managing all levels of chronic pain,” said CEO Dr Esra Ogru.

Phosphagenics (ASX:POH) was up 7% to 15.5c in morning trading today.